PMID: 6137388Jan 1, 1983Paper

Pharmacokinetics of triazolam in geriatric patients

European Journal of Clinical Pharmacology
O DehlinR B Smith


Serum triazolam levels were determined in eight geriatric patients (average age 80 years) on Days 1 and 7 of administration of triazolam 0.25 mg once daily, 1 h after a standard breakfast. Triazolam was rapidly absorbed reaching average peak concentrations of 2.0 and 2.04 ng/ml, 1.5 and 1.38 h after administration on Days 1 and 7, respectively. The mean apparent elimination half-life was 1.41 h (range 0.73-4.13 h) on Day 1 and 1.37 h (range 0.69-3.36 h) on Day 7. There was no significant difference between mean serum triazolam concentrations or pharmacokinetic parameters on Days 1 and 7 of the treatment. Serum samples were also assayed for alpha-hydroxytriazolam, an active metabolite of triazolam, but none could be detected in any of the samples from Days 1 or 7, assay sensitivity 0.09 ng/2 ml serum. The range of half-lives of triazolam in the patients in the present study is in close agreement with that previously reported in elderly subjects. The study provides further evidence of the lack of change in pharmacokinetic parameters on multiple dosing and that drug accumulation did not occur.


Mar 1, 1977·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Jul 1, 1976·Journal of Pharmaceutical Sciences·A J Sedman, J G Wagner
Jan 1, 1977·British Medical Journal·C M CastledenC Hallett
Sep 1, 1978·Clinical Pharmacokinetics·D J GreenblattE M Sellers
Jan 1, 1979·Journal of Clinical Pharmacology·S M MacLeodE M Sellers
Nov 1, 1977·Journal of Clinical Pharmacology·R I ShaderJ Koch-Weser
Feb 1, 1975·The Journal of Clinical Investigation·U KlotzG R Wilkinson
May 8, 1981·Journal of Chromatography·R Jochemsen, D D Breimer
Mar 1, 1983·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Jun 1, 1983·Journal of Clinical Psychopharmacology·R B SmithD J Greenblatt
Oct 1, 1981·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Mar 1, 1980·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader


Jan 1, 1990·European Journal of Clinical Pharmacology·H U FischJ Bircher
May 1, 1989·Journal of the American Geriatrics Society·R J Sullivan
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·R Jochemsen, D D Breimer
Jan 1, 1984·Journal of Clinical Pharmacology·H R OchsH Heuer
Jan 1, 1991·Infection·J H Winter
Sep 1, 1985·Drug Intelligence & Clinical Pharmacy·M L Britton, E S Waller

Related Concepts

Anti-Anxiety Effect

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.